Main Category: Arthritis / Rheumatology
Also Included In: Clinical Trials / Drug Trials
Article Date: 30 May 2011 – 0:00 PDT
email to a friend printer friendly opinions
<!– rate article
Patient / Public:Healthcare Prof:
The results of this study, conducted in Germany, re-open the debate on whether it is ethical to conduct placebo-controlled studies where patients in the placebo-group are at a serious disadvantage compared to patients taking the new treatments. The study analysed current study designs, for new therapies such as abatacept (Orencia®), golimumab (Simponi®) or tocilizumab (Actemra®), and showed that patients in the placebo group experienced no change in medication, having to continue with their former, ineffective treatment plus placebo.
“According to the Helsinki-Declaration of the World Medical Association*, a placebo-controlled study design is deemed to be ethically acceptable when there is no other effective treatment,” said Dr. Juche, Johanniter-Hospital, Treuenbrietzen, Germany. “However, this analysis confirms that patients in the placebo-group are at a disadvantage as they are given no change in medication to reduce their active inflammatory condition or halt disease progression. Our recommendation is that future clinical trials should include an active comparator group to ensure that all patients receive effective treatments to improve their quality of life.”
In the analysis, researchers used studies from the European Public Assessment Report (EPAR) of the European Medicines Agency (EMA) for abatacept, golimumab and tocilizumab as samples. The studies chosen had to be placebo controlled at the beginning and state clinical relevant outcome criteria (e.g. DAS28**, ACR20***, Health Assessment Questionnaire and joint erosion scores).
Abstract Number: FRI0339
*The World Medical Association (WMA) is an organisation promoting the highest possible standards of medical ethics. The WMA provides ethical guidance to physicians through its Declarations, Resolutions and Statements.
**DAS28 (Disease Activity Score) is an index used by physicians to measure how active an individual’s RA is.
***ACR (American College of Rheumatology) criteria measures improvement in tender or swollen joint counts.
European League Against Rheumatism
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.
Follow us on Twitter
Arthritis / Rheumatology headlines
email to a friend
printer friendly version
personalize your news
back to top
Please note that we publish your name, but we do not publish your email address. It is only used to let
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Terms and Conditions
MediLexicon International Ltd
MediLexicon International Ltd © 2004-2011 All rights reserved.